US2856415A
(en)
|
1957-11-13 |
1958-10-14 |
Searle & Co |
3,19-dihydroxy-5-androstene derivatives
|
FR1380417A
(fr)
|
1962-05-15 |
1964-12-04 |
Roussel Uclaf |
Nouveaux androstanyl-pyrazoles et procédé de préparation
|
US3206459A
(en)
|
1962-10-19 |
1965-09-14 |
Syntex Corp |
10alpha-pregnan-19-ol derivatives
|
US3169134A
(en)
|
1963-03-21 |
1965-02-09 |
Searle & Co |
2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
|
BE754111A
(fr)
|
1969-07-29 |
1971-01-29 |
Upjohn Co |
Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
|
GB1434919A
(en)
|
1972-06-15 |
1976-05-12 |
Glaxo Lab Ltd |
3alpha-hydroxy androstanes
|
US3953429A
(en)
*
|
1970-12-17 |
1976-04-27 |
Glaxo Laboratories Limited |
Anaesthetic steroids of the androstance and pregnane series
|
GB1380246A
(en)
*
|
1970-12-17 |
1975-01-08 |
Glaxo Lab Ltd |
3alpha-hydroxy-androstanes and esters thereof
|
US3943124A
(en)
|
1970-12-17 |
1976-03-09 |
Gordon Hanley Phillipps |
Chemical compounds
|
US3983111A
(en)
|
1972-05-05 |
1976-09-28 |
Glaxo Laboratories Limited |
Steroidal anaesthetics of the pregnane and 19-norpregnane series
|
GB1430942A
(en)
|
1972-05-05 |
1976-04-07 |
Glaxo Lab Ltd |
21-substituted 3alpha-hydroxy pregnanes
|
GB1436324A
(en)
|
1972-05-12 |
1976-05-19 |
Glaxo Lab Ltd |
Anaesthetic 3alpha-hydroxy pregnanes
|
ES432106A1
(es)
|
1973-11-30 |
1976-11-01 |
Schering Ag |
Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
DE2438020A1
(de)
|
1974-08-05 |
1976-02-26 |
Schering Ag |
18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
|
IL48628A0
(en)
|
1974-12-23 |
1976-02-29 |
Schering Ag |
D-homo-20-keto-pregnanes and process for their manufactur
|
DE2526373C2
(de)
|
1975-06-11 |
1983-11-10 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
|
US4192871A
(en)
|
1976-01-06 |
1980-03-11 |
Glaxo Laboratories Limited |
Chemical compounds
|
GB1570394A
(en)
|
1976-01-06 |
1980-07-02 |
Glaxo Lab Ltd |
11-acyloxy-3-hydroxy steroids
|
GB1581234A
(en)
*
|
1976-04-05 |
1980-12-10 |
Glaxo Operations Ltd |
11a - amino - 3a - hydroxysteroids
|
DE2632677A1
(de)
|
1976-07-16 |
1978-01-26 |
Schering Ag |
Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
|
GB1581235A
(en)
|
1977-04-04 |
1980-12-10 |
Glaxo Operations Ltd |
11a-amino-3a-hydroxy-steroids
|
US4389345A
(en)
|
1981-10-09 |
1983-06-21 |
G.D. Searle & Co. |
3-Oxoestra-17-acetonitrile and unsaturated analogs
|
US4495102A
(en)
|
1982-09-03 |
1985-01-22 |
G. D. Searle & Co. |
Aminoalkyl steroids
|
US5319115A
(en)
|
1987-08-25 |
1994-06-07 |
Cocensys Inc. |
Method for making 3α-hydroxy, 3β-substituted-pregnanes
|
US5120723A
(en)
|
1987-08-25 |
1992-06-09 |
University Of Southern California |
Method, compositions, and compounds for modulating brain excitability
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
EP0603312A4
(en)
|
1991-09-13 |
1995-06-07 |
Cocensys Inc |
NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
|
DE4232681C2
(de)
|
1992-09-29 |
1994-11-24 |
Sigma Tau Ind Farmaceuti |
17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
|
DE69435286D1
(de)
|
1993-05-24 |
2010-05-20 |
Purdue Pharma Ltd |
Verfahren und zusammensetzungen zum hervorrufen von schlaf
|
EP0656365B1
(en)
|
1993-12-02 |
1997-04-09 |
Akzo Nobel N.V. |
Substituted 2beta-morpholinoandrostane derivatives
|
CZ300694A3
(en)
|
1993-12-02 |
1996-05-15 |
Akzo Nobel Nv |
Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
|
US5939545A
(en)
|
1994-02-14 |
1999-08-17 |
Cocensys, Inc. |
Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
|
JP4066272B2
(ja)
|
1994-02-14 |
2008-03-26 |
ユーロ‐セルティック エス. ア. |
Gaba受容体のアロステリックな調節のためのアンドロスタン及びプレグナン類
|
AU3125695A
(en)
|
1994-07-21 |
1996-02-22 |
Pharmacia & Upjohn Company |
Neurologically active aminosteroids
|
ATE198753T1
(de)
|
1994-11-23 |
2001-02-15 |
Cocensys Inc |
Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors
|
UA57706C2
(uk)
|
1995-06-06 |
2003-07-15 |
Косенсіз, Інк |
Нейроактивні стероїди ряду андростанів та прегнанів, фармацевтична композиція і спосіб лікування (варіанти)
|
AU3967297A
(en)
*
|
1996-08-01 |
1998-02-25 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
US5994334A
(en)
|
1997-02-05 |
1999-11-30 |
University Of Maryland |
Androgen synthesis inhibitors
|
US5935545A
(en)
|
1997-07-11 |
1999-08-10 |
E. I. Du Pont De Nemours And Company |
Process for producing an aqueous solution comprising ferric chloride
|
DE69927960T2
(de)
|
1998-03-11 |
2006-07-20 |
Torbjörn Backström |
Epiallopregnanolon zur behandlung von krankheiten des cns
|
EP1177206A1
(en)
|
1999-04-29 |
2002-02-06 |
Purdue Pharma Ltd. |
3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anaesthetic activity
|
US7018406B2
(en)
|
1999-11-17 |
2006-03-28 |
Corevalve Sa |
Prosthetic valve for transluminal delivery
|
WO2001060836A1
(fr)
|
2000-02-18 |
2001-08-23 |
Taiho Pharmaceutical Co., Ltd. |
Procede de preparation de derives steroidiens
|
US6855836B2
(en)
|
2000-10-26 |
2005-02-15 |
Jenapharm Gmbh & Co. Kg |
17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
|
ES2287184T3
(es)
|
2000-11-03 |
2007-12-16 |
Washington University |
Estructuras aromaticas modificadas con sustituyentes hidroxi-, que tienen actividad citoprotectora.
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
WO2004085459A1
(en)
|
2003-03-24 |
2004-10-07 |
Sterix Limited |
Oestrogen derivatives as inhibitors of steroid sulphatase
|
WO2005000869A1
(en)
|
2003-05-29 |
2005-01-06 |
Washington University |
Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
|
EP1689767A1
(en)
|
2003-11-24 |
2006-08-16 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
US20090118248A1
(en)
|
2004-04-23 |
2009-05-07 |
Euro-Celtique S.A. |
3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
|
WO2006037016A2
(en)
*
|
2004-09-27 |
2006-04-06 |
The Regents Of The University Of California |
Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
WO2006110172A2
(en)
|
2004-09-29 |
2006-10-19 |
Hollis-Eden Pharmaceuticals.Inc. |
Steroid analogs and characterization and treatment methods
|
ES2344313T3
(es)
|
2005-06-09 |
2010-08-24 |
Euro-Celtique S.A. |
Composiciones farmaceuticas de un esteroide neuroactivo y usos de las mismas.
|
MX2009005335A
(es)
|
2006-11-21 |
2009-06-08 |
Umecrine Ab |
El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
|
US20090203658A1
(en)
|
2007-01-08 |
2009-08-13 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
DE102007027636A1
(de)
|
2007-06-12 |
2008-12-18 |
Bayer Schering Pharma Aktiengesellschaft |
17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
|
US8575375B2
(en)
|
2007-06-15 |
2013-11-05 |
Research Triangle Institute |
Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
|
GB0711948D0
(en)
|
2007-06-20 |
2007-08-01 |
Bionature E A Ltd |
Neurosteriod compounds
|
CN101412742B
(zh)
|
2007-10-19 |
2013-07-31 |
天津金耀集团有限公司 |
一种抑制血管新生的硝酸酯药物
|
US20090264443A1
(en)
|
2008-04-18 |
2009-10-22 |
David Helton |
Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
|
CN101624414B
(zh)
|
2008-07-07 |
2013-02-13 |
天津金耀集团有限公司 |
一种抑制血管新生的硝酸酯药物
|
CZ301216B6
(cs)
|
2008-07-10 |
2009-12-09 |
Ústav organické chemie a biochemie Akademie ved CR, v. v. i. |
Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
|
WO2010054158A2
(en)
|
2008-11-07 |
2010-05-14 |
Auspex Pharmaceuticals, Inc. |
Steroid modulators of glucocorticoid receptor
|
WO2011079047A1
(en)
|
2009-12-23 |
2011-06-30 |
Drugtech Corporation |
Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
|
US20130303500A1
(en)
|
2010-07-30 |
2013-11-14 |
Medexis S.A. |
Compounds and methods for treating neoplasia
|
US20120214987A1
(en)
|
2010-12-15 |
2012-08-23 |
Yu Ge |
Methods and compounds for preparing 3alpha-oxygen substituted steroids
|
WO2012109752A1
(en)
|
2011-02-15 |
2012-08-23 |
Socpra Sciences Et Génie, S.E.C. |
Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
|
CZ201181A3
(cs)
|
2011-02-15 |
2012-09-12 |
Ústav organické chemie a biochemie Akademie ved CR, v.v.i. |
Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
|
US9388210B2
(en)
|
2011-02-25 |
2016-07-12 |
Washington University |
Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
EP3296405B1
(en)
|
2011-03-23 |
2019-10-09 |
Etsuro Ito |
Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate
|
EP2736919A4
(en)
|
2011-07-29 |
2015-01-14 |
Univ California |
NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
|
CN107936076B
(zh)
|
2011-09-08 |
2021-10-15 |
萨奇治疗股份有限公司 |
神经活性类固醇、组合物、及其用途
|
US20150291654A1
(en)
|
2011-10-14 |
2015-10-15 |
Sage Therapeutics, Inc. |
3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
|
CN112472814A
(zh)
|
2012-01-23 |
2021-03-12 |
萨奇治疗股份有限公司 |
神经活性类固醇制剂和治疗中枢神经系统障碍的方法
|
US20150175651A1
(en)
|
2012-06-15 |
2015-06-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
CA3028207A1
(en)
|
2012-06-19 |
2013-12-27 |
Intercept Pharmaceuticals, Inc. |
Preparation, uses and solid forms of obeticholic acid
|
WO2014028398A2
(en)
|
2012-08-13 |
2014-02-20 |
The Regents Of The University Of California |
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
|
PT2887944T
(pt)
|
2012-08-21 |
2022-01-10 |
Sage Therapeutics Inc |
Alopregnanolona para tratamento do estado de mal epiléptico refratário
|
US9765110B2
(en)
|
2012-10-08 |
2017-09-19 |
Washington University |
Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
EP2916846A4
(en)
*
|
2012-11-09 |
2016-08-10 |
Goodchild Invest Pty Ltd |
NEUROACTIVE STEROIDS AND THEIR USE TO FACILITATE NEUROPROTECTION
|
AU2013352141B2
(en)
|
2012-11-30 |
2018-04-05 |
The Regents Of The University Of California |
Anticonvulsant activity of steroids
|
SI2935307T1
(en)
|
2012-12-18 |
2018-08-31 |
Washington University |
Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures
|
US8939545B2
(en)
|
2012-12-20 |
2015-01-27 |
Eastman Kodak Company |
Inkjet printing with managed airflow for condensation control
|
WO2014108808A2
(en)
|
2013-01-09 |
2014-07-17 |
Henry James Lorne |
Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
|
CA2831054C
(en)
|
2013-01-09 |
2016-08-30 |
Sapna Life Sciences Corp. |
Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
|
GB201302368D0
(en)
|
2013-02-11 |
2013-03-27 |
Univ Bath |
Compound
|
US9512170B2
(en)
|
2013-03-01 |
2016-12-06 |
Washington University |
Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
|
US9562026B2
(en)
|
2013-03-14 |
2017-02-07 |
Washington University |
Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
|
US20160068563A1
(en)
|
2013-04-17 |
2016-03-10 |
Boyd L. Harrison |
19-nor neuroactive steroids and methods of use thereof
|
EP3909966A1
(en)
|
2013-04-17 |
2021-11-17 |
Sage Therapeutics, Inc. |
19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy
|
WO2014169831A1
(en)
*
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
|
EP2986624B1
(en)
*
|
2013-04-17 |
2020-03-25 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids for methods of treatment
|
RS61733B1
(sr)
|
2013-07-19 |
2021-05-31 |
Sage Therapeutics Inc |
Neuroaktivni steroidi, njihove kompozicije i upotrebe
|
PT3488852T
(pt)
|
2013-08-23 |
2021-02-03 |
Sage Therapeutics Inc |
Esteroides neuroativos, composições e seus usos
|
WO2015180679A1
(en)
|
2014-05-29 |
2015-12-03 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
WO2015195962A1
(en)
|
2014-06-18 |
2015-12-23 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
WO2016036724A1
(en)
|
2014-09-02 |
2016-03-10 |
The Texas A&M University System |
Method of treating organophosphate intoxication
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
NZ731034A
(en)
|
2014-10-16 |
2024-02-23 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
NZ731095A
(en)
|
2014-10-16 |
2023-12-22 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
HUE049014T2
(hu)
|
2014-11-27 |
2020-09-28 |
Sage Therapeutics Inc |
Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
|
JP6745274B2
(ja)
|
2015-01-26 |
2020-08-26 |
セージ セラピューティクス, インコーポレイテッド |
Cns障害を処置するための組成物および方法
|
CN105985396A
(zh)
|
2015-02-16 |
2016-10-05 |
苏州泽璟生物制药有限公司 |
氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
|
US10329320B2
(en)
|
2015-02-20 |
2019-06-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
WO2016164763A1
(en)
|
2015-04-10 |
2016-10-13 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
MA45276A
(fr)
|
2015-06-18 |
2018-04-25 |
Sage Therapeutics Inc |
Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
|
UY36741A
(es)
|
2015-06-21 |
2016-12-30 |
Prevacus Inc |
Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
|
CN108350021A
(zh)
|
2015-09-08 |
2018-07-31 |
视点医疗公司 |
用于治疗眼科疾病的化合物和制剂
|
KR20180082457A
(ko)
|
2015-10-16 |
2018-07-18 |
마리누스 파마슈티컬스 인코포레이티드 |
나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
|
US20200306262A1
(en)
|
2015-11-20 |
2020-10-01 |
Sage Therapeutics, Inc. |
Compounds and methods of their use
|
TWI798173B
(zh)
|
2016-03-08 |
2023-04-11 |
美商賽吉醫療公司 |
神經活性類固醇,其組合物及用途
|
US10226550B2
(en)
|
2016-03-11 |
2019-03-12 |
Brigham Young University |
Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
|
EP3481845B1
(en)
|
2016-07-11 |
2023-09-13 |
Sage Therapeutics, Inc. |
C17, c20, and c21 substituted neuroactive steroids and their methods of use
|
JP7065825B2
(ja)
|
2016-07-11 |
2022-05-12 |
セージ セラピューティクス, インコーポレイテッド |
C7、c12、およびc16置換神経刺激性ステロイドおよびそれらの使用方法
|
JOP20190022B1
(ar)
|
2016-08-23 |
2023-03-28 |
Sage Therapeutics Inc |
ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
CN108727453A
(zh)
|
2017-04-20 |
2018-11-02 |
华东理工大学 |
新型pd-1抑制剂及其应用
|
WO2019018119A1
(en)
|
2017-07-18 |
2019-01-24 |
Pairnomix, Llc |
METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
|
US11285139B2
(en)
|
2017-08-31 |
2022-03-29 |
Takeda Pharmaceutical Company Limited |
Treatment of CNS conditions
|
CN117771252A
(zh)
|
2017-09-07 |
2024-03-29 |
萨奇治疗股份有限公司 |
神经活性甾类及其使用方法
|
WO2019051477A1
(en)
|
2017-09-11 |
2019-03-14 |
Sage Therapeutics, Inc. |
METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
|
JP2020534270A
(ja)
|
2017-09-14 |
2020-11-26 |
セージ セラピューティクス, インコーポレイテッド |
19−ノルc3,3−二置換c21−n−ピラゾリルステロイドおよびその使用方法
|
KR20200085837A
(ko)
|
2017-11-10 |
2020-07-15 |
마리누스 파마슈티컬스 인코포레이티드 |
유전적 간질 질환 치료에 사용하기 위한 가낙솔론의 용도
|
KR20200096596A
(ko)
|
2017-12-08 |
2020-08-12 |
세이지 테라퓨틱스, 인크. |
Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
|
MX2020006608A
(es)
|
2017-12-22 |
2020-11-06 |
Sage Therapeutics Inc |
Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
|
KR20200104350A
(ko)
|
2017-12-22 |
2020-09-03 |
세이지 테라퓨틱스, 인크. |
Cns 장애의 치료를 위한 조성물 및 방법
|
MA51568A
(fr)
|
2018-01-12 |
2021-04-21 |
Sage Therapeutics Inc |
Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
|
CN112533611A
(zh)
|
2018-06-12 |
2021-03-19 |
萨奇治疗股份有限公司 |
19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
|
CA3115805A1
(en)
|
2018-10-12 |
2020-04-16 |
Sage Therapeutics, Inc. |
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
|
WO2020082065A1
(en)
|
2018-10-19 |
2020-04-23 |
Sage Therapeutics, Inc. |
9(11)-unsaturated neuroactive steroids and their methods of use
|
CN113383004A
(zh)
|
2018-12-05 |
2021-09-10 |
萨奇治疗股份有限公司 |
神经活性类固醇及其使用方法
|
JP2022514385A
(ja)
|
2018-12-21 |
2022-02-10 |
セージ セラピューティクス, インコーポレイテッド |
3α-ヒドロキシ-17β-アミド神経刺激性ステロイドおよびその組成物
|
TW202110824A
(zh)
|
2019-05-24 |
2021-03-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|
JOP20210293A1
(ar)
|
2019-05-31 |
2023-01-30 |
Sage Therapeutics Inc |
ستيرويدات ذات فعالية عصبية وتركيبات منها
|
AR119305A1
(es)
|
2019-06-27 |
2021-12-09 |
Sage Therapeutics Inc |
Composiciones y métodos para el tratamiento de los trastornos del snc
|
US20230085354A1
(en)
|
2019-06-27 |
2023-03-16 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
US20230257415A1
(en)
|
2019-06-27 |
2023-08-17 |
Sage Therapeutics, Inc. |
Compounds for treating cns disorders
|
MX2022006533A
(es)
|
2019-12-05 |
2023-03-01 |
Sage Therapeutics Inc |
Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
|
TW202143976A
(zh)
|
2020-03-18 |
2021-12-01 |
美商賽吉醫療公司 |
神經活性類固醇及其使用方法
|
PE20221911A1
(es)
|
2020-03-25 |
2022-12-23 |
Sage Therapeutics Inc |
Uso de agentes para el tratamiento de condiciones respiratorias
|
EP4172171A1
(en)
|
2020-06-24 |
2023-05-03 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
|
AU2021312240A1
(en)
|
2020-07-20 |
2023-02-02 |
Sage Therapeutics, Inc. |
Formulations of 19-nor C3,3- disubstituted C21-n-pyrazolyl steroid and methods of use thereof
|
KR20230124916A
(ko)
|
2020-11-25 |
2023-08-28 |
세이지 테라퓨틱스, 인크. |
Cns 장애를 치료하기 위한 조성물 및 방법
|
JP2024507638A
(ja)
|
2021-01-28 |
2024-02-21 |
セージ セラピューティクス, インコーポレイテッド |
性機能障害処置のための神経刺激性ステロイドの使用
|
WO2022177718A1
(en)
|
2021-02-18 |
2022-08-25 |
Sage Therapeutics, Inc. |
Use of neuroactive steroid for treatment of sexual dysfunction
|
TW202300156A
(zh)
|
2021-03-17 |
2023-01-01 |
美商賽吉醫療公司 |
用於治療重度憂鬱症之19-nor-c3,3-二取代c21-n-吡唑基類固醇
|
KR20230170716A
(ko)
|
2021-04-12 |
2023-12-19 |
세이지 테라퓨틱스, 인크. |
본태성 진전 치료
|
CN117580580A
(zh)
|
2021-04-29 |
2024-02-20 |
萨奇治疗股份有限公司 |
用于在哺乳期女性中治疗重度抑郁障碍和产后抑郁症的神经活性类固醇
|
EP4329770A1
(en)
|
2021-04-29 |
2024-03-06 |
Sage Therapeutics, Inc. |
19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
|